02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

ICT-121: Completed Phase I enrollment

ImmunoCellular completed enrollment of 20 patients with HLA-A2 positive GBM in an open-label, U.S. Phase I trial to evaluate ICT-121. Patients will receive ICI-121 once weekly for 4 weeks followed by maintenance treatment every 2...
07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: GD3 ganglioside; ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 (ST8SIA1); prominin 1 (PROM1; CD133)

Cancer INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting GD3 ganglioside or its synthetic enzyme ST8SIA1 could help treat glioblastoma multiforme (GBM). In patients, tumor levels of GD3 ganglioside and ST8SIA1...
07:00 , May 19, 2014 |  BioCentury  |  Emerging Company Profile

Curtana: Curtains for CSCs

Curtana Pharmaceuticals Inc. is developing small molecule inhibitors of OLIG2 , a transcription factor that may maintain cancer stem cells that help glioblastoma multiforme resist and bounce back from cancer therapy. GBM was seen as...
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Glioblastoma Epidermal growth factor receptor variant III (EGFRvIII); prominin 1 (PROM1; CD133) Studies in patient samples and mice suggest a bispecific...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Clinical News

ICT-121: Phase I started

ImmunoCellular said investigators at Cedars-Sinai Medical Center began an open-label, U.S. Phase I trial to evaluate ICI-121 in about 20 patients who have had gross tumor resection and experience a first recurrence of GBM and...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Prominin 1 (PROM1; CD133) Mouse studies suggest oncolytic measles viruses engineered to target CD133 could help treat cancer. CD133 is a marker of stem...
07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Cord blood-derived induced neuronal cells (CB-iNCs) In vitro and mouse studies suggest human CB-iNCs could be used to treat and study neuronal disorders. In isolated...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

Pfizer preclinical data

In mouse xenograft models of TNBC, PF-03084014 in combination with docetaxel led to reduced tumor growth and greater onset of apoptosis vs. either treatment alone. The combination also reduced the frequency of prominin 1 (...